5,744 Shares in Twist Bioscience Corporation $TWST Purchased by E Fund Management Co. Ltd.

Posted by George Bondi on Aug 21st, 2026

E Fund Management Co. Ltd. acquired a new position in shares of Twist Bioscience Corporation (NASDAQ:TWST – Free Report) in the 2nd quarter, according to its most recent filing with the SEC. The fund acquired 5,744 shares of the company’s stock, valued at approximately $591,000.

Several other hedge funds and other institutional investors have also made changes to their positions in TWST. Quarry LP purchased a new position in Twist Bioscience in the 3rd quarter valued at $28,000. Western Wealth Management LLC purchased a new stake in shares of Twist Bioscience during the first quarter worth $31,000. Strs Ohio acquired a new stake in shares of Twist Bioscience in the first quarter valued at about $33,000. Strategic Advocates LLC lifted its stake in shares of Twist Bioscience by 562.7% in the fourth quarter. Strategic Advocates LLC now owns 1,067 shares of the company’s stock worth $34,000 after buying an additional 906 shares in the last quarter. Finally, SBI Securities Co. Ltd. boosted its position in Twist Bioscience by 68.9% during the fourth quarter. SBI Securities Co. Ltd. now owns 1,400 shares of the company’s stock worth $44,000 after acquiring an additional 571 shares during the last quarter.

Twist Bioscience Trading Down 4.3%

TWST opened at $136.33 on Friday. The stock has a market capitalization of $8.55 billion, a PE ratio of -61.41 and a beta of 2.14. Twist Bioscience Corporation has a one year low of $23.30 and a one year high of $145.51. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.38 and a current ratio of 2.67. The business’s 50 day moving average price is $99.30 and its 200 day moving average price is $69.80.

Twist Bioscience (NASDAQ:TWST – Get Free Report) last posted its earnings results on Monday, August 3rd. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.05). Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%.The business had revenue of $118.38 million for the quarter, compared to analyst estimates of $114.55 million. During the same period last year, the business earned $0.33 EPS. Twist Bioscience’s revenue was up 23.2% compared to the same quarter last year. As a group, equities research analysts expect that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Insiders Place Their Bets

In other Twist Bioscience news, CEO Emily M. Leproust sold 113,318 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $125.16, for a total value of $14,182,880.88. Following the transaction, the chief executive officer owned 818,938 shares of the company’s stock, valued at $102,498,280.08. This represents a 12.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Dennis Cho sold 14,205 shares of the stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $89.75, for a total transaction of $1,274,898.75. Following the transaction, the insider directly owned 105,141 shares of the company’s stock, valued at approximately $9,436,404.75. This trade represents a 11.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 151,529 shares of company stock valued at $17,708,772. 3.08% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts have commented on TWST shares. Barclays increased their price objective on shares of Twist Bioscience from $65.00 to $95.00 and gave the company an “overweight” rating in a report on Wednesday, June 24th. Robert W. Baird upped their price target on Twist Bioscience from $113.00 to $115.00 and gave the company an “outperform” rating in a research report on Tuesday, August 4th. Evercore cut Twist Bioscience from an “outperform” rating to an “in-line” rating and set a $102.00 price target for the company. in a report on Monday, July 6th. Canaccord Genuity Group lifted their price objective on Twist Bioscience from $90.00 to $120.00 and gave the stock a “buy” rating in a research report on Tuesday, July 14th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Twist Bioscience in a research note on Wednesday, June 24th. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Twist Bioscience has a consensus rating of “Moderate Buy” and a consensus target price of $98.30.

Get Our Latest Analysis on Twist Bioscience

Twist Bioscience Company Profile

(Free Report)

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.